Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

 Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

Shots:

  • The companies collaborated to evaluate IMU-838 (DHODH inhibitors) + NHC (nucleoside analogues) to treat patients with viral infections including COVID-19 and Influenza
  • The preclinical research showed that IMU-838 strongly synergizes with selected nucleoside analogues to inhibit SARS-CoV-2 replication in vitro. In vitro test system, IMU-838 & NHC alone showed 99.9% & 99% reduction in viral RNA at concentrations of 5μM & 100 nM
  • The enrollment of the first patient in the P-II CALLIPER trial of IMU-838 for MS is expected in Sept’21 & for the P-III ENSURE program in Q4’21. Additionally, the P-II results of IMU-838 in UC is expected to be available in Q2’22

Click here to­ read full press release/ article | Ref: Immunic | Image: PR Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post